Mandal Arundhati, Raju Sheena, Viswanathan Chandra
Regenerative Medicine, Reliance Life Sciences Pvt Ltd, Dhirubhai Ambani Life Sciences Centre, R-282, TTC Industrial Area of MIDC, Thane Belapur Road, Rabale, Navi Mumbai, 400 701, India.
In Vitro Cell Dev Biol Anim. 2016 Feb;52(2):243-51. doi: 10.1007/s11626-015-9956-1. Epub 2015 Oct 20.
Human embryonic stem cells (hESCs) are predicted to be an unlimited source of hepatocytes which can pave the way for applications such as cell replacement therapies or as a model of human development or even to predict the hepatotoxicity of drug compounds. We have optimized a 23-d differentiation protocol to generate hepatocyte-like cells (HLCs) from hESCs, obtaining a relatively pure population which expresses the major hepatic markers and is functional and mature. The stability of the HLCs in terms of hepato-specific marker expression and functionality was found to be intact even after an extended period of in vitro culture and cryopreservation. The hESC-derived HLCs have shown the capability to display sensitivity and an alteration in the level of CYP enzyme upon drug induction. This illustrates the potential of such assays in predicting the hepatotoxicity of a drug compound leading to advancement of pharmacology.
人类胚胎干细胞(hESCs)有望成为肝细胞的无限来源,可为细胞替代疗法、人类发育模型等应用铺平道路,甚至可用于预测药物化合物的肝毒性。我们优化了一种23天的分化方案,以从hESCs中生成肝细胞样细胞(HLCs),获得了一个相对纯化的群体,该群体表达主要的肝脏标志物且具有功能且成熟。即使经过长时间的体外培养和冷冻保存,HLCs在肝特异性标志物表达和功能方面的稳定性仍保持完好。hESC来源的HLCs已显示出在药物诱导时表现出敏感性以及CYP酶水平改变的能力。这说明了此类检测在预测药物化合物肝毒性从而推动药理学发展方面的潜力。